Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab.

ABSTRACT: Thyroid eye disease (TED) causes orbital soft-tissue expansion. Recent studies have suggested that brow and temple changes may also occur. Teprotumumab, a monoclonal antibody to the insulin-like growth factor 1 receptor reduces soft-tissue swelling in TED. In this study, we quantified the changes to pan facial soft-tissue volumes and eyelid position, following treatment with teprotumumab.

Methods

In this prospective study, consecutive patients who were treated with teprotumumab were appraised for study eligibility. All patients had 3D facial imaging using the Vectra H2. Soft-tissue volume changes in the upper face, periorbita, temples, midface, and lower face were quantified before and after teprotumumab therapy. Furthermore, the marginal reflex distance (MRD)1, MRD2, and intercanth

SUBMITTER: Ugradar S 

PROVIDER: S-EPMC8443810 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature